WHO WE ARE Celluminova is a life science startup company specializing in identification of cancer stem cells. Our first indication is for malignant gliomas (aggressive brain tumors). THE GLIOMA STEM CELL PROBLEM Glioma stem cells are believed to be major drivers of tumor recurrence and are resistant to chemotherapy and radiation. Currently, no methods exist to identify or target these cells in patients. OUR SOLUTION Celluminova has developed a molecule specifically targeting glioma stem cells. Our patented compound, p-HTMI, is intended for application during brain surgery. p-HTMI is a fluorescent molecule that illuminates glioma stem cells, enabling neurosurgeons to distinguish between healthy and cancerous tissue within minutes. OUR COMMITMENT Research suggests that failure to target glioma stem cells explains the poor survival of aggressive brain tumor patients. Therefore, the ability to specifically detect and remove these cells could potentially result in improved patient outcomes. The benefit of patients is our main focus.
There is no investment information
No recent news or press coverage available for Celluminova.